Yoav H Messinger
Overview
Explore the profile of Yoav H Messinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chappell T, Pflaster E, Namata R, Bell J, Miller L, Pomputius W, et al.
J Pediatr Hematol Oncol
. 2024 Nov;
47(1):e26-e33.
PMID: 39526966
Childhood acute myeloid leukemia (AML) requires intensive chemotherapy, which may result in life-threatening bloodstream infections (BSIs). This study evaluated whether machine learning (ML) could predict BSI using electronic medical records....
2.
Schultz K, Nelson A, Mallinger P, Harris A, Kamihara J, Baldinger S, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5681-5692.
PMID: 39400264
Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of...
3.
Arad-Cohen N, Attias O, Zohar Y, Messinger Y
Front Oncol
. 2024 Sep;
14:1441318.
PMID: 39281382
This case report describes a 2-month-old girl with acute megakaryoblastic leukemia (AMKL) harboring the t(1;22)(p13;q13) translocation, resulting in the RBM15::MRTFA fusion gene. She presented with massive hepatosplenomegaly and liver fibrosis...
4.
Schoettler P, Smith C, Nishitani M, Harris A, Nelson A, Watson D, et al.
Pediatr Blood Cancer
. 2024 May;
71(8):e31090.
PMID: 38807260
Background: Anaplastic sarcoma of the kidney (ASK) is a DICER1-related neoplasm first identified as a distinctive tumor type through the evaluation of unusual cases of putative anaplastic Wilms tumors. Subsequent...
5.
Nelson A, Harris A, Watson D, Kamihara J, Chen K, Stall J, et al.
Gynecol Oncol
. 2024 Apr;
186:117-125.
PMID: 38657450
Objective: Sertoli-Leydig cell tumors (SLCTs) are rare sex cord-stromal tumors, representing <0.5% of all ovarian tumors. We sought to describe prognostic factors, treatment and outcomes for individuals with ovarian SLCT....
6.
Hoover A, Watson D, Reimche P, Tanner L, Gilchrist L, Finch M, et al.
BMC Res Notes
. 2024 Apr;
17(1):112.
PMID: 38644484
Objective: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and among the most common malignancies in young adults and requires a unique pattern of healthcare utilization including an...
7.
Nelson A, Vasta L, Watson D, Kim J, Harris A, Best A, et al.
Thorax
. 2024 Mar;
79(7):644-651.
PMID: 38508719
Background: Pleuropulmonary blastoma (PPB), the hallmark tumour associated with -related tumour predisposition, is characterised by an age-related progression from a cystic lesion (type I) to a high-grade sarcoma with mixed...
8.
Wagner Y, Adam D, Pomeranz Engelberg G, Pomeranz A, Messinger Y
Pediatric Health Med Ther
. 2024 Mar;
15:111-120.
PMID: 38469429
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal hyperinflammatory cytokine storm. It can be secondary to infections, malignancies, autoimmune diseases, or the manifestation of genetic disorders, including primary immune deficiency....
9.
Hayashi R, Hermiston M, Wood B, Teachey D, Devidas M, Chen Z, et al.
Blood
. 2024 Mar;
143(20):2053-2058.
PMID: 38457359
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or...
10.
Hoover A, Reimche P, Watson D, Tanner L, Gilchrist L, Finch M, et al.
Cancer Rep (Hoboken)
. 2024 Jan;
7(2):e1980.
PMID: 38217445
Background: B-lineage acute lymphoblastic leukemia (B-ALL) is the most common malignancy of childhood. With the introduction of novel cellular therapies, cost of care is a critical component and the financial...